Copy to clipboard 
Treace Medical reported 1Q25 orthopedic sales of $52.6 million, up 2.9% compared to the first quarter of 2024.
The company faced a difficult prior-year comparison and one less selling day in this quarter. Adjusted for selling days, Treace grew 4.5% compared to the first quarter last year.
The company has effectively captured, on average, 25% of its surgeons’ bunion cases. With three new bunion correction systems (Nanoplasty and Percuplasty 3D MIS Osteotomy Systems and the SpeedMTP MTP Fusion System), Treace now has access to the remaining 75% of those surgeons’ cases.
“Our R&D engine is running open throttle and delivering a robust pipeline of new technologies that we believe will further extend our market leadership position,” said Treace Medical CEO and Founder John Treace. “As we envisioned from the start, this year, we will be establishing Treace as the one-stop shop with a suite of differentiated best-in-class bunion systems that will drive our top line growth this year into 2026 and beyond.”
Given timing around surgical schedules and normal seasonality, the company expects revenue growth to accelerate each quarter.
For the full year, Treace expects sales between $224 million and $230 million, representing growth between 7% and 10%.
Orthopedic Sales Data
Unless otherwise noted, all orthopedic sales data is provided in USD millions. We estimate orthopedic sales and growth rates on an as-reported basis.
Orthopedic Sales by Segment
| Segment | 1Q25 | 1Q24 | $ Chg | % Chg |
|---|---|---|---|---|
| Trauma | $52.6 | $51.1 | $1.5 | 2.9% |
Company Earnings
| Amt | % of Sales | |
|---|---|---|
| Sales | $52.6 | |
| Cost of Sales | $10.7 | 20.3% |
| Sales and Marketing | $36.1 | 68.7% |
| General and Admin | $15.8 | 30% |
| R & D | $5.6 | 10.6% |
| Other | $0.3 | 0.6% |
| Net Earnings | ($15.9) | (30.3%) |
Treace Medical reported 1Q25 orthopedic sales of $52.6 million, up 2.9% compared to the first quarter of 2024.
The company faced a difficult prior-year comparison and one less selling day in this quarter. Adjusted for selling days, Treace grew 4.5% compared to the first quarter last year.
The company has effectively captured, on...
Treace Medical reported 1Q25 orthopedic sales of $52.6 million, up 2.9% compared to the first quarter of 2024.
The company faced a difficult prior-year comparison and one less selling day in this quarter. Adjusted for selling days, Treace grew 4.5% compared to the first quarter last year.
The company has effectively captured, on average, 25% of its surgeons’ bunion cases. With three new bunion correction systems (Nanoplasty and Percuplasty 3D MIS Osteotomy Systems and the SpeedMTP MTP Fusion System), Treace now has access to the remaining 75% of those surgeons’ cases.
“Our R&D engine is running open throttle and delivering a robust pipeline of new technologies that we believe will further extend our market leadership position,” said Treace Medical CEO and Founder John Treace. “As we envisioned from the start, this year, we will be establishing Treace as the one-stop shop with a suite of differentiated best-in-class bunion systems that will drive our top line growth this year into 2026 and beyond.”
Given timing around surgical schedules and normal seasonality, the company expects revenue growth to accelerate each quarter.
For the full year, Treace expects sales between $224 million and $230 million, representing growth between 7% and 10%.
Orthopedic Sales Data
Unless otherwise noted, all orthopedic sales data is provided in USD millions. We estimate orthopedic sales and growth rates on an as-reported basis.
Orthopedic Sales by Segment
| Segment | 1Q25 | 1Q24 | $ Chg | % Chg |
|---|---|---|---|---|
| Trauma | $52.6 | $51.1 | $1.5 | 2.9% |
Company Earnings
| Amt | % of Sales | |
|---|---|---|
| Sales | $52.6 | |
| Cost of Sales | $10.7 | 20.3% |
| Sales and Marketing | $36.1 | 68.7% |
| General and Admin | $15.8 | 30% |
| R & D | $5.6 | 10.6% |
| Other | $0.3 | 0.6% |
| Net Earnings | ($15.9) | (30.3%) |
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
ME
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.
